Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21182267 | 0.85 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL26401540 | 0.84 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL21921098 | 0.84 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL13020439 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL20231023 | 0.82 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL26401405 | 0.82 | HTT (0.43) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL26401534 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL20089414 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL20037956 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL22043316 | 0.78 | CACNA1I (0.40) | CHRNB2CHRNA4ALDH1A1MAPTCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142878-B1 | PYRIDINE INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230212123-A1 | Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same | UNIV MICHIGAN REGENTS (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2021221953-A1 | PYRIDINE INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-108137579-A | Bridging piperidine derivative | 豪夫迈·罗氏有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-7582770-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-2010493-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | CHRNB2 245/4885CHRNA4 122/4885CHRNB1 416/4885 |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, TRPV1, SCN1A | CHRNB2 485/4885CHRNA4 436/4885CHRNB1 696/4885 |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | CHRNB2 442/4885CHRNA4 414/4885CHRNB1 557/4885 |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | CHRNB2 245/4885CHRNA4 380/4885CHRNB1 457/4885 |
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | CHRNB2 4314/4885CHRNA4 4266/4885CHRNB1 3432/4885 |
| US-20230212123-A1 | Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same | GBA1, GAA, GBA2 | CHRNB2 3138/4885CHRNA4 2765/4885CHRNB1 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.